InMed Pharmaceuticals Inc., announces that their research partner, the University of British Columbia (UBC), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) for their collaborative efforts with InMed in the biosynthesis of cannabinoids.
NSERC has committed funding of C$136,000 over the course of three years to the research revolving around cannabinoid biosynthesis. The collaboration is called the ‘Microbial metabolic engineering for cannabinoid biosynthesis’, which originally commenced in May 2015, targets development of a microbial-based cannabinoid expression system for the manufacture of individual cannabinoid drugs for treating diseases with high unmet medical needs.
InMed’s vice president, Pre-Clinical Research & Development, Eric Hsu, Ph.D., comments, “We are honored that our trusted, world-class research partner, Dr. Yadav at UBC, has received this prestigious grant from the NSERC. Through our continued research effort on this program with UBC, we remain optimistic that the development of our proprietary biosynthesis platform technology will result in commercial-scale manufacturing of cannabinoids.”
“We would like to take this opportunity to extend our gratitude to the NSERC for their vote of confidence in our cutting-edge work,” adds Vikramaditya G. Yadav, Ph.D., assistant professor in the Department of Chemical & Biological Engineering. “The successful completion of this Collaboration will not only advance the Company’s manufacturing capabilities and its R&D pipeline, but also provide immense social and strategic benefit to Canada.”
